Horia Stefanescu

Dr. Horia Stefanescu

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2016 in Hepatology
Verified
Journal Article
Closed access
PDF file
JAJuan G. Abraldes
Juan G. Abraldes
CBChristophe Bureau
Christophe Bureau
HSHoria Stefanescu
Horia Stefanescu
SASalvador Augustin
Salvador Augustin
MNMichael Ney
Michael Ney
FIfor the Anticipate Investigators
for the Anticipate Investigators

25 June 2019 in Ultraschall in der Medizin - European Journal of Ultrasound
Verified
Journal Article
Closed access
PDF file
ASAdrian Saftoiu
Adrian Saftoiu
OGOdd Helge Gilja
Odd Helge Gilja
KHKing's College Hospital
King's College Hospital
CDChristoph F. Dietrich
Christoph F. Dietrich
VCVito Cantisani
Vito Cantisani
PVPeter Vilmann
Peter Vilmann
This manuscript describes the use of ultrasound elastography, with the exception of liver applications, and represents an update of the 2013 EFSUMB (European Federation of Societies for Ultrasound in Medicine and Biology) Guidelines and Recommendations on the clinical use of elastography. Diese Arbeit beschreibt den Einsatz der Ultraschall-Elastografie mit Ausnahme der Leberanwendungen und ist eine Aktualisierung der Leitlinien und Empfehlungen der EFSUMB (European Federation of Societies for Ultrasound in Medicine and Biology) von 2013 zum klinischen Einsatz der Elastografie. * All authors contributed equally to the manuscript.

30 October 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
SASalvador Augustin
Salvador Augustin
MPMonica Pons
Monica Pons
JMJames B. Maurice
James B. Maurice
CBChristophe Bureau
Christophe Bureau
HSHoria Stefanescu
Horia Stefanescu
JGJoan Genescà
Joan Genescà

22 December 2010 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
HSHoria Stefanescu
Horia Stefanescu
MGMircea Grigorescu
Mircea Grigorescu
Monica Lupsor-PlatonMonica Lupsor-Platon
Monica Lupsor-Platon
BPBogdan Procopet
Bogdan Procopet
AMAnca Maniu
Anca Maniu
RBRadu Badea
Radu Badea

27 November 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
JAJuan Pablo Arab
Juan Pablo Arab
LDLuis Antonio Díaz
Luis Antonio Díaz
JRJürgen Rehm
Jürgen Rehm
GIGene Im
Gene Im
MAMarco Arrese
Marco Arrese
PMPhilippe Mathurin
Philippe Mathurin

11 December 2018 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
IPI. Pettinari
I. Pettinari
RVR. Vukotic
R. Vukotic
HSHoria Stefanescu
Horia Stefanescu
APA. Pecorelli
A. Pecorelli
MMMc Morelli
Mc Morelli
TSThe Bo-Lives (Bologna Liver Vascular Studies)
The Bo-Lives (Bologna Liver Vascular Studies)
Objectives: Portal vein thrombosis (PVT) is a frequent complication of cirrhosis. Benefit, safety, and duration of anticoagulant treatment in this setting are controversial issues. The aim of this study was to analyze the course of PVT in a large cohort of cirrhotic patients undergoing or not anticoagulation therapy. Methods: The data of 182 patients who presented between January 2008 and March 2016 with cirrhosis and PVT with at least 3 months of follow-up after the first PVT detection were analyzed. Eighty-one patients received anticoagulants and 101 were untreated per physician discretion. Results: The extension of the thrombosis decreased by >50% in 46 (56.8%, with complete recanalization in 31/46) patients under anticoagulation and in 26 (25.7%) untreated patients. Of the 46 patients who underwent recanalization, 17 (36%) suffered recurrent thrombosis after stopping anticoagulation therapy. Kaplan–Meier analysis showed a higher survival rate in the treated group (p = 0.010). At multivariate analysis, anticoagulation was an independent factor associated with longer survival (HR:0.30, CI:0.10–0.91, p = 0.014). The Child–Turcotte–Pugh classes B/C negatively influenced survival (hazard ratio, (HR):3.09, confidence interval (CI):1.14–8.36, p = 0.027 for Child–Turcotte–Pugh B and HR:9.27, CI:2.67–32.23, p < 0.001 for Child–Turcotte–Pugh C). Bleeding complications occurred in 22 (21.8%) untreated and 16 (19.7%) treated patients, but in only four cases was it judged to be related to the anticoagulant treatment. No death was reported as a consequence of the bleeding events. Conclusions: Anticoagulant treatment is a safe and effective treatment leading to partial or complete recanalization of the portal venous system in 56.8% of cases, improving the survival of patients with cirrhosis and PVT. Discontinuation of the therapy is associated with a high rate of PVT recurrence.